Divalproex Sodium Patent Expiration
Divalproex Sodium is Used for managing and preventing seizures in epilepsy and sometimes used for treating migraine headaches. It was first introduced by Abbvie Inc
Divalproex Sodium Patents
Given below is the list of patents protecting Divalproex Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Depakote Er |
US6419953 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6511678 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6528090 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6528091 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6713086 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6720004 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er | US6419953 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6511678 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6528090 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6528091 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6713086 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6720004 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
Divalproex Sodium's Family Patents
